//fpnotebook.com/
Phosphodiesterase-4 Inhibitor
Aka: Phosphodiesterase-4 Inhibitor, Roflumilast, Daliresp
- See Also
- COPD Management
- Mechanism
- Phosphodiesterase-4 Inhibitor increases lung, intracellular cAMP
- Indications
- Severe, refractory COPD with frequent exacerbations
- Dosing
- Roflumilast 500 mcg orally daily ($250/month)
- Adverse Effects
- Gastrointestinal (common, intolerable in 5%)
- Diarrhea
- Nausea
- Weight loss (may be >10%)
- Other common symptoms
- Headache
- Insomnia
- Psychiatric (3%)
- Suicidality
- Depression
- Anxiety
-
Drug Interactions
- Cytochrome P450 3A4 Inhibitors
- Cytochrome P450 3A4 and Cytochrome P450 1A2 Inducers
- Efficacy
- NNT: 24 severe COPD patients to prevent 1 hospitalization per year
- Does not reduce mortality
- References
- (2015) Presc Lett 22(5): 27
- Field (2011) Circ Respir Pulm Med 5: 57–70 [PubMed]